Por: ABC News Business June 11, 2023
NEW YORK -- Gene sequencing test maker Illumina Inc. said Sunday that its board has accepted the resignation of its CEO and director, Francis deSouza, effective immediately.Charles Dadswell, senior vice president and general counsel, has been named interim CEO, while the board conducts a search for a new CEO. Illumina said deSouza, who has been with the company since 2013 and was named CEO three years later, will stay on in an advisory capacity... + full article
MarketWatch USA Business May 25, 2023
Illumina is holding its annual meeting at 1 p.m. Eastern time, at which the results of the proxy vote will be announced. The meeting will be held virtually, and is only open to shareholders. The stakes are high for Icahn, who needs a win. The Wall Street lion is facing an from a... + más
Biotech company Illumina pushes back against Carl Icahn’s proxy fight over $7.1 billion Grail deal | CNBC
Illumina ordered by FTC to unwind $7b Grail deal from 2021 | The Boston Globe
ABC News USA Business May 25, 2023
WASHINGTON -- The business empire of corporate raider and activist investor Carl Icahn continues to tumble amid the fallout following a recent report from short-selling firm Hindenburg Research — and losses are accelerating as a longtime rival echoes the firm's... + más
Icahn Enterprises continues to tumble following Hindenburg short report, Bill Ackman's responses | Associated Press
Activist investor Icahn becomes target of short seller | The Boston Globe
The New York Times USA Business April 03, 2023
The Federal Trade Commission on Monday ordered Illumina, the leading maker of gene-sequencing machines, to divest Grail, a cancer-test developer.The move by the F.T.C. is the latest development in a case seen by antitrust experts as a to stop big companies from buying fledgling... + más
FTC orders Illumina to unwind $7B deal for cancer test developer Grail | Fox Business
Fox Business USA Business April 03, 2023
Check out whats clicking on FoxBusiness.com The on Monday ordered life sciences company Illumina to unwind its $7.1 billion acquisition of cancer detection test developer Grail Inc., citing antitrust concerns. The commission voted unanimously in a 4-0 decision to force Illumina... + más
F.T.C. Orders Gene-Sequencing Company Illumina to Divest Acquisition | The New York Times
CNBC USA Health March 24, 2023
In this articleCarl Icahn speaking at Delivering Alpha in New York on Sept. 13, 2016.David A. Grogan CNBCCarl Icahn on Friday alleged that 's directors demanded extra personal liability insurance before the biotech company signed off on a $7.1 billion acquisition of cancer... + más
Icahn proposes three candidates for Illumina’s board — Here’s what could be next in the battle | CNBC
CNBC USA Health March 21, 2023
In this articleCarl IcahnAdam Jeffery CNBC Biotech company pushed back Monday against Carl Icahn's proxy fight over the company's acquisition of cancer test developer Grail, saying the activist investor's board nominees do not add value. The San Diego-based DNA... + más
Carl Icahn claims Illumina directors got extra insurance to close 'disastrous' $7.1 billion Grail deal | CNBC
CNBC USA Business March 18, 2023
Business: develops, manufactures and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and Grail. Grail, which was acquired in , is a health-care company focused on early detection of... + más
About iurex | Privacy Policy | Disclaimer |